ArticleJHLT open2026
Management of Tacrolimus-induced thrombotic microangiopathy in a heart transplant recipient: Utilizing novel immunosuppression strategies.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathy (TMA) represents a heterogeneous group of disorders characterized by endothelial injury, complement activation, and platelet aggregation, and may occur in association with systemic diseases, infections, or drug exposure. In solid organ transplant recipients, TMA is most commonly linked to immunosuppressive therapy, particularly calcineurin inhibitors and mammalian target of rapamycin inhibitors, with increased risk during combined use. Drug-induced TMA is rare but potentially life-threatening, and management relies primarily on prompt withdrawal of the offending agent and modification of immunosuppression. We report the successful use of belatacept-based immunosuppression in a heart transplant recipient with tacrolimus-associated TMA. Belatacept, a selective T-cell costimulation blocker, represents a promising alternative immunosuppressive strategy in this setting, particularly in patients with drug-related vascular toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.